Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Thomson

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Plant Physiology|June 23, 2010
A SQUAMOSA MADS box gene involved in the regulation of anthocyanin accumulation in bilberry fruitsLaura Jaakola, Mervin Poole, Matthew O Jones, et al.
Journal of the American Heart Association|July 2, 2016
Plasma Macrophage Migration Inhibitor Factor Is Elevated in Response to Myocardial IschemiaFenling Fan, Lu Fang, Xiao-Lei Moore, et al.
Plos One|May 1, 2008
Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trialsWendy Stevens, Anatoli Kamali, Etienne Karita, et al.
The Lancet Regional Health. Western Pacific|June 30, 2022
Genomic epidemiology of <i>Salmonella</i> Typhi in Central Division, Fiji, 2012 to 2016Mark R Davies, Sebastian Duchene, Mary Valcanis, et al.
Vaccine|October 10, 2025
Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trialTsetsegsaikhan Batmunkh, Eleanor F G Neal, Otgonjargal Amraa, et al.
The Lancet Regional Health. Western Pacific|February 15, 2024
Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trialTsetsegsaikhan Batmunkh, Kerryn A Moore, Helen Thomson, et al.
Frontiers in Immunology|April 8, 2026
Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trialTsetsegsaikhan Batmunkh, Eleanor Fg Neal, Otgonjargal Amraa, et al.
Plos One|September 30, 2010
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in AfricaWalter Jaoko, Etienne Karita, Kayitesi Kayitenkore, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Plant Physiology|June 23, 2010
A SQUAMOSA MADS box gene involved in the regulation of anthocyanin accumulation in bilberry fruitsLaura Jaakola, Mervin Poole, Matthew O Jones, et al.
Journal of the American Heart Association|July 2, 2016
Plasma Macrophage Migration Inhibitor Factor Is Elevated in Response to Myocardial IschemiaFenling Fan, Lu Fang, Xiao-Lei Moore, et al.
Plos One|May 1, 2008
Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trialsWendy Stevens, Anatoli Kamali, Etienne Karita, et al.
The Lancet Regional Health. Western Pacific|June 30, 2022
Genomic epidemiology of <i>Salmonella</i> Typhi in Central Division, Fiji, 2012 to 2016Mark R Davies, Sebastian Duchene, Mary Valcanis, et al.
Vaccine|October 10, 2025
Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trialTsetsegsaikhan Batmunkh, Eleanor F G Neal, Otgonjargal Amraa, et al.
The Lancet Regional Health. Western Pacific|February 15, 2024
Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trialTsetsegsaikhan Batmunkh, Kerryn A Moore, Helen Thomson, et al.
Frontiers in Immunology|April 8, 2026
Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trialTsetsegsaikhan Batmunkh, Eleanor Fg Neal, Otgonjargal Amraa, et al.
Plos One|September 30, 2010
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in AfricaWalter Jaoko, Etienne Karita, Kayitesi Kayitenkore, et al.
Pageof 3